The stock of Arbutus Biopharma Corp (NASDAQ: ABUS) has decreased by -1.17 when compared to last closing price of 3.83. Despite this, the company has experienced a -3.20% fall in its stock price over the last five trading sessions. zacks.com reported 2024-09-25 that Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Is It Worth Investing in Arbutus Biopharma Corp (NASDAQ: ABUS) Right Now?
Company’s 36-month beta value is 1.92.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABUS is 146.67M, and currently, short sellers hold a 4.47% ratio of that floaft. The average trading volume of ABUS on October 02, 2024 was 1.15M shares.
ABUS’s Market Performance
The stock of Arbutus Biopharma Corp (ABUS) has seen a -3.20% decrease in the past week, with a -5.14% drop in the past month, and a 19.78% gain in the past quarter. The volatility ratio for the week is 3.62%, and the volatility levels for the past 30 days are at 4.72% for ABUS. The simple moving average for the last 20 days is -9.46% for ABUS stock, with a simple moving average of 21.72% for the last 200 days.
Analysts’ Opinion of ABUS
Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Buy.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 02, 2022 of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $5. The rating they have provided for ABUS stocks is “Hold” according to the report published on February 25th, 2021.
H.C. Wainwright gave a rating of “Buy” to ABUS, setting the target price at $10 in the report published on December 17th of the previous year.
ABUS Trading at -3.94% from the 50-Day Moving Average
After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.89% of loss for the given period.
Volatility was left at 4.72%, however, over the last 30 days, the volatility rate increased by 3.62%, as shares sank -6.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.65% lower at present.
During the last 5 trading sessions, ABUS fell by -2.69%, which changed the moving average for the period of 200-days by +74.54% in comparison to the 20-day moving average, which settled at $4.17. In addition, Arbutus Biopharma Corp saw 51.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABUS starting from MANCHESTER KEITH S, who sale 8,846 shares at the price of $3.69 back on Aug 14 ’24. After this action, MANCHESTER KEITH S now owns 46,069 shares of Arbutus Biopharma Corp, valued at $32,637 using the latest closing price.
Sims Karen, the Chief Medical Officer of Arbutus Biopharma Corp, sale 4,358 shares at $2.31 during a trade that took place back on Feb 02 ’24, which means that Sims Karen is holding 125,542 shares at $10,078 based on the most recent closing price.
Stock Fundamentals for ABUS
Current profitability levels for the company are sitting at:
- -8.21 for the present operating margin
- 0.86 for the gross margin
The net margin for Arbutus Biopharma Corp stands at -7.66. The total capital return value is set at -0.6. Equity return is now at value -59.96, with -45.77 for asset returns.
Based on Arbutus Biopharma Corp (ABUS), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -11.34. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -1087.28.
Currently, EBITDA for the company is -76.63 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of 65.43. The receivables turnover for the company is 4.87for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.56.
Conclusion
In a nutshell, Arbutus Biopharma Corp (ABUS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
